ClinDev Strategy IQ Pharma R&D Β· Clinical Development Strategy Platform
← Portfolio
βš™οΈ Module 01 Β· Clinical Trial Feasibility

Clinical Trial Feasibility AI

Country prioritization, site selection, and enrollment forecasting for global clinical trial design. Inputs flow into a multi-factor scoring engine weighing patient pool, regulatory speed, site experience, competitive density, and cost index.

πŸŽ›οΈ Trial Inputs
Target Enrollment 450
I/E Criteria Strictness 7
Number of Sites 35
Overall Feasibility
72
out of 100
β–² Moderate-High
Time to FPI
7.4
months (median)
vs 8.2 benchmark
Enrollment Duration
16.8
months to LPI
β–² -2.1 vs base
Est. Total Cost
$48.6M
trial budget
Β±15% range
πŸ—ΊοΈ Country Prioritization Heatmap 8 countries scored

Multi-factor country scoring across 5 dimensions. Dark cells indicate stronger feasibility for the selected indication.

Country
Patient Pool
Reg. Speed
Site Quality
Competition
Cost Index
Composite
πŸ₯ Top-Ranked Sites PI track record Β· Past enrollment Β· IRB cycle
Site / Institution Country PI Experience Hist. Enroll Rate IRB Cycle Feasibility Score Tier
πŸ“ˆ Enrollment Forecast (24 months) Monte Carlo p10 / p50 / p90

Cumulative randomized patients across base, optimistic, and conservative scenarios β€” based on site count, recruitment rate per site-month, and seasonal drop-offs.

⚑ AI Strategic Insight
For NSCLC Phase 2 with 450-patient target across 35 sites, the model recommends a US + Western EU + Asia-Pacific mix. Spain and South Korea are unexpectedly strong on the Pareto frontier (high site quality Γ— low competitive density). Consider de-prioritizing US-only sites in major academic centers due to competitive trial saturation (~14 active NSCLC IO trials at MSK, MD Anderson, Dana-Farber) β€” this will erode enrollment velocity by an estimated 28%.
  • Risk flag: I/E strictness of 7/10 with biomarker requirement implies ~32% screen-fail rate. Plan for 1.5Γ— over-screening capacity.
  • Operating model implication: Hybrid in-house + CRO model for 35 sites across 8 countries β€” full CRO outsourcing adds $7-9M and 2.4 months.
  • Regulatory cadence: Tier-1 countries (US, Germany, UK) enable parallel IND/CTA filings β€” staged approach saves 3.2 months on global FPI.
πŸ“‹ Module 02 Β· Protocol Design

Protocol Design Optimizer

Score and stress-test trial protocol design across endpoint reliability, eligibility complexity, sample size, and amendment risk. Benchmarks against industry-standard protocols by phase and therapeutic area.

πŸŽ›οΈ Protocol Inputs
Inclusion Criteria Count 12
Exclusion Criteria Count 22
Biomarker Requirement 2
Visit Frequency (per month) 2
Protocol Complexity
7.8
vs 6.4 industry avg
β–² +22% complexity
Est. Screen Fail Rate
34%
based on I/E + biomarker
β–² Above target
Amendment Risk
62%
prob. β‰₯1 substantial amend.
Moderate
Pt. Burden Index
5.6
out of 10
β–² DCT-reduced
🎯 Endpoint Quality Matrix
πŸ“Š Complexity vs Industry Benchmark
⚠️ Protocol Risk Diagnostic
Risk DriverCurrent ScoreIndustry P50RecommendationΞ” Impact
⚑ Optimization Recommendation
Protocol scores 7.8 / 10 on complexity β€” above the industry P75 (7.2). The main drivers: 34 total I/E criteria, dual biomarker requirement, and bi-weekly clinic visits. Three high-leverage simplifications:
  • Consolidate exclusion criteria β€” 8 of 22 exclusions are duplicative of historical safety profile; removing them reduces screen-fail by ~6 percentage points without changing risk-benefit.
  • Move 4 PK timepoints to home-based dried blood spot β€” drops patient burden 1.4 points, supports DCT positioning for FDA/EMA.
  • Lock primary endpoint at PFS, move ORR + DoR to secondary β€” reduces alpha-spending split and improves statistical power by 11%.
Amendment risk reduction: Estimated 62% β†’ 41% with above changes, avoiding ~$2.4M in median amendment costs.
🎯 Module 03 · Drug Development Strategy

R&D Portfolio Strategy

Asset-level prioritization across the R&D portfolio. Plots probability of technical and regulatory success (PTRS) against risk-adjusted NPV to generate Prioritize / Pause / Partner / Divest recommendations.

Portfolio Assets
12
across 4 therapeutic areas
Risk-Adj. NPV (Total)
$8.4B
expected lifetime value
β–² $1.2B vs LY
Avg. PTRS
31%
portfolio-weighted
vs 28% industry
5-Yr R&D Spend
$3.2B
cumulative
β–Ό +14% YoY
πŸ“Š PTRS Γ— NPV Portfolio Matrix 12 assets Β· Bubble = R&D spend to launch

Strategic quadrants: Prioritize (high PTRS, high NPV) Β· Partner (high NPV, lower PTRS) Β· Optimize (high PTRS, lower NPV) Β· Divest/Pause (low both).

πŸ’Š Therapeutic Area Allocation
Phase Distribution
πŸ“‹ Asset-Level Recommendations Prioritize Β· Partner Β· Optimize Β· Divest
Asset Indication Phase PTRS Peak Sales ($B) Risk-Adj. NPV ($M) R&D to Launch ($M) Recommendation
⚑ Portfolio Strategic Brief
Portfolio is over-indexed on early-phase oncology (47% of spend, 31% of risk-adjusted NPV). Three high-leverage rebalancing moves:
  • Prioritize: ASC-301 (NSCLC, Phase 3, PTRS 64%) and IMD-118 (UC, Phase 2, PTRS 48%) β€” combined risk-adj NPV $3.1B. Accelerate to FPI within 6 months.
  • Partner / Out-license: NEU-204 (early MS, Phase 1) β€” strong scientific rationale but capability gap in neuro late-stage. Consider deal with established CNS player.
  • Divest / Pause: CDM-091 (Type 2 diabetes, Phase 2) β€” PTRS 14%, NPV negative under competitive forecast (GLP-1 saturation). Redeploy $180M to oncology priority assets.
R&D operating model implication: Capability buildout needed in immunology biomarker discovery and adaptive trial design β€” recommend Center of Excellence model rather than hiring siloed function leads.
βš–οΈ Module 04 Β· Regulatory Affairs

Regulatory Pathway Selector

Recommends optimal regulatory pathways across FDA, EMA, PMDA, and NMPA based on innovation level, unmet need, existing evidence base, and breakthrough / fast-track eligibility. Compares parallel vs sequential submission strategies.

πŸŽ›οΈ Regulatory Profile
πŸ›€οΈ Recommended Regulatory Pathway High Confidence (87%)
πŸ“… Multi-Region Timeline Comparison

Time-to-approval scenarios across major regulators. Bars represent pre-IND/CTA through approval.

🀝 Agency Interaction Plan
Meeting / SubmissionAgencyTimingStrategic PurposePriority
⚑ Regulatory Strategic Brief
For an NME in a rare disease with high unmet need + moderate Phase 2 evidence, the optimal pathway is FDA Breakthrough Therapy Designation + Accelerated Approval, paralleled with EMA PRIME + Conditional Marketing Authorization. PMDA SAKIGAKE designation is additive if Japan is a launch market.
  • Surrogate endpoint strategy: Confirm with FDA Type B meeting before Phase 3 design lock β€” biomarker validation reduces full-approval timeline by 18-24 months.
  • Parallel filing risk: Concurrent US/EU/Japan filing requires CMC alignment β€” recommend single global manufacturing strategy from Phase 2b.
  • Post-marketing commitments: Plan for confirmatory Phase 4 trial as accelerated approval condition β€” design embedded in pivotal study extension to minimize incremental cost.
πŸ—οΈ Module 05 Β· R&D Operating Model

R&D Operating Model Diagnostic

Function-by-function maturity assessment across Clinical Operations, Regulatory, Pharmacovigilance, Biostatistics, Data Sciences, and Medical Affairs. Benchmarks cycle time, FTE allocation, and outsourcing posture against industry peers.

Composite Maturity
3.4
out of 5.0 (industry P50: 3.6)
β–² Below benchmark
Avg. Trial Cycle Time
7.8
months FPI β†’ DBL
β–² +1.2 vs P50
Outsourcing Mix
58%
CRO / FSP spend
vs 62% peer
Cost per Patient
$94K
portfolio-weighted
β–Ό -8% YoY
πŸ•ΈοΈ Function Maturity Radar

Current state vs target state vs industry P75 across 6 R&D functions.

⏱️ Cycle Time Benchmarks

Time-to-milestone vs industry P25 / P50 / P75.

πŸ“Š Function-Level Diagnostic
R&D FunctionCurrent MaturityTargetIndustry P75Key GapPriority
⚑ Operating Model Transformation Roadmap
Composite maturity of 3.4 / 5.0 places the organization in the industry P40 β€” below peer median. Three transformation priorities with highest ROI:
  • Year 1 β€” Data Sciences buildout: Largest gap (current 2.4 vs target 4.0). Establish a centralized AI/ML CoE for trial feasibility, RWE, and protocol optimization. Estimated $18M investment, ~9-month payback through cycle time reduction.
  • Year 2 β€” Clinical Operations target operating model: Shift from study-by-study CRO model to therapeutic-area FSP partnerships with 3 strategic CROs. Reduces cycle time 1.4 months and CRO spend 12%.
  • Year 3 β€” Regulatory and PV consolidation: Move from regional model to global functional model with embedded therapeutic area leads. Single source of truth platform across IND/CTA/MAA submissions.
Total expected impact: Composite maturity 3.4 β†’ 4.1, cycle time -2.1 months per trial, $42M cumulative cost takeout over 3 years, +8% improvement in trial start-up KPIs.
πŸ—ΊοΈ Module 06 Β· Clinical Development Plan

Clinical Development Plan (CDP) Architect

End-to-end clinical development timeline with phase-by-phase planning, go/no-go gates, budget allocation, and risk-adjusted milestones. Integrates with portfolio strategy and regulatory pathway to generate launch-ready CDPs.

Target Launch
Q2 2031
5.3 years from now
Total R&D Investment
$612M
FIH β†’ Approval
β–² +8% vs P50
Cumulative PTRS
47%
Phase 2 β†’ Approval
β–² Above benchmark
Go/No-Go Gates
5
decision points
πŸ“… Integrated Development Timeline

Risk-adjusted phase timeline with parallel work streams. Bars sized by phase duration; milestones above.

πŸ’° R&D Budget Allocation by Phase
🎯 Go/No-Go Decision Gates
GateTimingCriteriaPTRS Ξ”
⚑ CDP Strategic Brief
Target launch Q2 2031 requires aggressive parallelization of Phase 2 dose-finding with biomarker validation. Three timeline-critical decisions:
  • Phase 2 design: Recommend adaptive 2-stage design (Simon's two-stage or Bayesian adaptive) β€” accelerates decision point by 4 months vs traditional Phase 2a/2b sequential.
  • Regulatory parallelization: File IND + CTA + JIND in lockstep starting Q3 2026. Type B meeting Q1 2027 to confirm Phase 3 endpoints and accelerated approval pathway.
  • Phase 3 readiness: Lock Phase 3 protocol design 12 weeks before EoP2 meeting. Pre-allocate CMC scale-up budget to avoid late-stage manufacturing bottleneck.
Risk-adjusted scenario: Base case launch Q2 2031 ($612M). Aggressive scenario Q4 2030 with breakthrough designation (-$48M, -2 quarters). Conservative scenario Q4 2031 if Phase 2 amends required.
Analysis updated